Advertisement

WHO pauses hydroxychloroquine coronavirus trial over safety concerns

Coronavirus outbreak: WHO says uncertainty in hydroxycholoroquine resulted in pause of solidarity trial
Dr. Soumiya Swaminathan, chief scientist of the World Health Organization (WHO), explained on Monday that the hydroxychloroquine “arm” of the COVID-19 treatment Solidarity Trial was paused for enrollment due to the uncertainty surrounding the drug after a study published showed a potential higher mortality rate among COVID-19 patients taking the drug. She said the measures are temporary in order to examine published and unpublished studies on the drug.

The World Health Organization said Monday that it will temporarily drop hydroxychloroquine — the malaria drug U.S. President Trump says he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date.

In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be “a temporary pause” on the hydroxychloroquine arm of its global clinical trial.

READ MORE: Big study finds Trump-backed malaria drugs not helpful treatment for coronavirus

“This concern relates to the use of hydroxychloroquine and chloroquine in COVID-19,” Tedros said, adding that the drugs are approved treatments for people with malaria or autoimmune diseases. Other treatments in the trial, including the experimental drug remdesivir and an HIV combination therapy, are still being tested.

Story continues below advertisement

Tedros said the executive group behind WHO’s global “Solidarity” trial met on Saturday and decided to conduct a comprehensive review of all available data on hydroxychloroquine and that its use in the trial would be suspended for now.

Coronavirus outbreak: Study finds hydroxychloroquine may be tied to higher fatality risk for COVID-19 patients
Coronavirus outbreak: Study finds hydroxychloroquine may be tied to higher fatality risk for COVID-19 patients

Dr. Michael Ryan, WHO’s emergencies chief, said there was no indication of any safety problems with hydroxychloroquine in the WHO trial to date, but that statisticians would now analyze the information.

[ Sign up for our Health IQ newsletter for the latest coronavirus updates ]

“We’re just acting on an abundance of caution based on the recent results of all the studies to to ensure that we can continue safely with that arm of the trial,” he said. WHO said it expected to have more details within the next two weeks.

READ MORE: Trump says he’s taking hydroxychloroquine as preventive measure against COVID-19

Story continues below advertisement

Last week, Trump announced he was taking hydroxychloroquine although he has not tested positive for COVID-19. His own administration has warned the drug can have deadly side effects, and both the European Medicines Agency and the U.S. Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings due to numerous serious side effects that in some cases can be fatal.

READ MORE: Canadian lupus patients missing critical drug after claims it treats coronavirus

Hydroxychloroquine and chloroquine are approved for treating lupus and rheumatoid arthritis and for preventing and treating malaria, but no large rigorous tests have found them safe or effective for preventing or treating COVID-19.